Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 13/20 | 0.51 |
| ▸ | DDB1 | Q16531 | 4/20 | 0.51 |
| ▸ | ESR1 | P03372 | 5/20 | 0.51 |
| ▸ | GSPT1 | P15170 | 2/20 | 0.47 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 4/20 | 0.45 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | WIZ | O95785 | 1/20 | 0.44 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30493346 | 0.99 | CRBN (0.51) | CRBNDDB1ESR1GSPT1IKZF3 | |
| SCHEMBL25935046 | 0.99 | CRBN (0.51) | CRBNDDB1ESR1GSPT1IKZF3 | |
| SCHEMBL25935228 | 0.99 | CRBN (0.51) | CRBNDDB1ESR1GSPT1IKZF3 | |
| SCHEMBL30493241 | 0.99 | CRBN (0.51) | CRBNDDB1ESR1GSPT1IKZF3 | |
| SCHEMBL30741736 | 0.98 | CRBN (0.51) | CRBNDDB1ESR1GSPT1IKZF3 | |
| SCHEMBL30493359 | 0.95 | CRBN (0.53) | CRBNDDB1ESR1GSPT1IKZF3 | |
| SCHEMBL20231967 | 0.95 | CRBN (0.53) | CRBNDDB1ESR1GSPT1IKZF3 | |
| SCHEMBL27311010 | 0.93 | CRBN (0.49) | CRBNDDB1ESR1GSPT1IKZF3 | |
| SCHEMBL21070542 | 0.93 | CRBN (0.49) | CRBNDDB1ESR1GSPT1IKZF3 | |
| SCHEMBL31134412 | 0.90 | CRBN (0.53) | CRBNDDB1ESR1GSPT1IKZF3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4466260-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | Astrazeneca AB (SE) | 2024-11-27 | — | — | EP | disclosed |
| WO-2023139199-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2023-07-27 | — | — | WO | disclosed |
| WO-2023139199-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2023-07-27 | — | — | WO | disclosed |